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        The zinc fi  nger transcription factor GATA-1 
serves as a useful paradigm for studying the role 
of lineage-specifi  c factors in cell fate determi-
nation. Its expression is restricted to select cell 
types within the hematopoietic system, includ-
ing erythroid, megakaryocytic, eosinophilic, 
and mast cells (  1  ). Its only site of expression 
outside of the hematopoietic system is in Ser-
toli cells of the testis (  2  ). Gene targeting stud-
ies in mice demonstrate an essential role for 
GATA-1 in erythroid and megakaryocytic ter-
minal maturation (  3  –  5  ). This activity requires 
direct physical interaction between GATA -1 
and its cofactor, friend of GATA-1 (FOG-1; 
also known as   zfpm1  ), a large multitype zinc 
fi  nger  –  containing protein (  6  –  10  ). In humans, 
germline missense mutations that disrupt the 
binding of GATA-1 to FOG-1 lead to severe 
thrombocytopenia and dyserthropoietic ane-
mia, in some cases necessitating bone marrow 
transplantation (  11  –  14  ). 
  Both GATA-1 and FOG-1 belong to fam-
ilies of proteins, whose members are expressed in 
overlapping patterns in diverse tissues. There are 
six known GATA factor genes ( GATA-1  ,  -2  ,  -3  , 
  -4  ,   -5  , and   -6  ) and two FOG genes (  FOG-1   
and  -2  ) in vertebrates. All GATA factor members 
contain highly conserved amino acid sequences 
within their amino zinc fi  nger that mediate 
binding to FOG proteins (  15  ). The requirement 
for direct interaction between GATA and FOG 
family members extends beyond GATA-1 and 
FOG-1. Interaction between GATA-2, another 
hematopoietic-expressed GATA factor, and 
FOG-1 is required during early megakaryopoi-
esis in the absence of GATA-1  –  FOG-1 binding 
(  9  ). Interaction between GATA-4 and FOG-2, 
two nonhematopoietic-expressed family mem-
bers, is required for normal cardiac and gonadal 
development (  16  –  19  ). Thus, GATA  –  FOG pro-
tein interactions are required in broad develop-
mental settings. 
  Despite the critical role that FOG proteins 
play in modulating GATA factor activity, their 
mechanism of action remains incompletely 
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  The zinc fi  nger transcription factor GATA-1 requires direct physical interaction with the 
cofactor friend of GATA-1 (FOG-1) for its essential role in erythroid and megakaryocytic 
development. We show that in the mast cell lineage, GATA-1 functions completely inde-
pendent of FOG proteins. Moreover, we demonstrate that FOG-1 antagonizes the fate 
choice of multipotential progenitor cells for the mast cell lineage, and that its down-
regulation is a prerequisite for mast cell development. Remarkably, ectopic expression of 
  FOG-1   in committed mast cell progenitors redirects them into the erythroid, megakaryo-
cytic, and granulocytic lineages. These lineage switches correlate with transcriptional 
down-regulation of   GATA-2  , an essential mast cell GATA factor, via switching of GATA-1 
for GATA-2 at a key enhancer element upstream of the   GATA-2   gene. These fi  ndings 
illustrate combinatorial control of cell fate identity by a transcription factor and its 
co  factor, and highlight the role of transcriptional networks in lineage determination. 
They also provide evidence for lineage instability during early stages of hematopoietic 
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erythroid progenitors (MEPs), and low levels of   FOG-1   in 
common lymphoid progenitors and granulocyte/macrophage 
progenitors (GMPs; along with low levels of   GATA-2  ).   
In contrast, MCPs cultured for 3 d in the cytokine cocktail 
described earlier in this paragraph express relatively high 
levels of   GATA-1   and   GATA-2   but no detectable   FOG-1  . 
The same is true of primary peritoneal mast cells. Thus, 
  FOG-1   expression is specifi  cally down-regulated as multi-
potent progenitor cells commit to the mast cell lineage. 
    FOG-2  , the only other known mammalian   FOG   gene, is 
thought to be expressed predominantly outside of the hema-
topoietic system (  15, 34, 35  ). However, to rule out a possible 
role in mast cell development, we performed RT-PCR anal-
ysis for   FOG-2   expression in primary mouse bone marrow  –
  derived mast cells (BMMCs). As shown in   Fig. 1 C  , we found 
no detectable   FOG-2   mRNA transcripts in these cells despite 
robust signals for the mast cell genes   mouse mast cell protease 2   
(  MMCP2  ),   MMCP-4  , and   mast cell carboxypeptidase A   (  MC-
CPA  ) in the same sample, and amplifi  cation of  FOG-2   mRNA 
transcripts from control heart tissue. 
  It is possible that FOG genes are expressed at levels below 
our detection limit or that yet additional FOG genes exist. To 
examine these possibilities, we analyzed yolk sac  –  derived mast 
cells (YSMCs) from knock-in mice containing substitution of 
valine 205 of GATA-1 by glycine (GATA-1  V205G  ). This muta-
tion markedly impairs FOG-1 binding, resulting in lethal ane-
mia and impaired megakaryopoiesis in mice (  8, 9  ). A similar 
mutation (GATA-1  V205M  ) causes severe X-linked dyserythro-
poietic anemia and thrombocytopenia in humans, and the ho-
mologous mutation in GATA-4 (GATA-4  V217G  ) blocks binding 
to FOG-2 (  11, 19  ). Because of the embryonic lethality of 
the mice, it was not possible to examine BMMCs. Instead, we 
cultured embryonic day 9.5 YSMCs in the presence of IL-3 and 
SCF for 6 wk, conditions typically used to generate BMMCs. 
These cells morphologically resemble BMMCs and express 
equivalent levels of the mast cell genes   MC-CPA  ,   MMCP-4  , 
  MMCP-5  ,   tryptophan hydroxylase  , and   microphthalmia-associated 
transcription factor   (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20070544/DC1). As shown in   Fig. 1 D  , 
YSMCs cultured from wild-type embryos are highly granular in 
appearance and nearly all coexpress c-kit and Fc    RI on their cell 
surface. In contrast, YSMCs from male GATA-1        embryos are 
hypogranular and have markedly impaired Fc    RI surface ex-
pression, consistent with previous reports of GATA-1  low   mast cells 
(  28  –  31  ). A smaller population of c-kit       Fc    RI        cells is also present 
in these cultures. Importantly, cells cultured from GATA-1  V205G   
male embryo yolk sacs resemble those derived from wild-type, 
and not GATA-1       , embryos in morphology and Fc    RI surface 
expression. We conclude that, in contrast to the erythroid and 
megakaryocyte lineages, GATA functions completely indepen-
dent of FOG proteins in terminal mast cell development. 
  Inhibition of mast cell development by FOG-1 in vitro 
and in vivo 
  Could FOG-1 actually antagonize mast cell development? 
This possibility was suggested by the results of yolk sac colony 
  understood (for review see reference   20  ). To date, no sequence-
specifi  c high affi   nity DNA binding activity of FOG proteins 
has been identifi  ed. This infers that FOG proteins exert their 
infl  uence via protein –  protein interactions. Chromatin immuno-
precipitation (ChIP) studies indicate that FOG-1 facilitates 
occ      upancy by GATA-1 at selected cis-regulatory chromatin 
elements in hematopoietic cells via a mechanism involving the 
switching of GATA-1 for GATA-2 (  21, 22  ). However, the 
molecular details of this activity are unknown. FOG family pro-
teins also interact with at least two transcriptional corepressor 
complexes: the C-terminal binding protein (CtBP) and the 
NuRD chromatin remodeling/histone deacetylase tran-
scriptional complexes (  23  –  27  ). The physiological signifi  cance 
of CtBP binding is not clear given that homozygous FOG-1 
knock-in mice containing mutations that disrupt CtBP binding 
are viable, fertile, and have normal hematopoiesis (  24  ). Interac-
tion with the NuRD complex has not been fully examined 
in vivo as of yet. 
  Work over the past several years has shown that GATA-1 
also plays a functional role in the terminal stages of mast cell 
maturation, particularly on expression of the high affi   nity IgE 
receptor (Fc    RI) (  28  –  32  ). A previous study from our group 
showed that   FOG-1   expression is absent in cultured mast cell 
lines, suggesting a possible FOG-independent GATA-1 func-
tion in the mast cell lineage (  6  ). In this study, we extend these 
fi  ndings using primary cells and gene-targeted mice to show 
that indeed GATA-1 functions independent of FOG protein in 
terminal mast cell maturation. Moreover, we show that FOG-1 
potently represses cell fate choice for the mast cell lineage dur-
ing early multipotent progenitor cell lineage commitment. Re-
markably, ectopic expression of FOG-1 in prospectively isolated 
mast cell progenitors (MCPs) redirects them into erythroid, 
megakaryocytic, and granulocytic lineages. Collectively, these 
observations identify FOG-1 as a key negative regulator of mast 
cell lineage choice, and demonstrate combinational control of 
cell fate decisions by a transcription factor and its cofactor. 
    RESULTS   
  FOG-independent function of GATA-1 in mast 
cell development 
  Previously, we reported that   FOG-1   expression is absent 
in the mouse mast cell lines P615 and HC.3 (  6  ). However, 
its expression in primary mast cells has not been reported. 
We recently identifi  ed a bipotent basophil/MCP cell popu-
lation that can be immunophenotypically isolated from the 
mouse spleen (Lin       c-kit  +  Fc    RII/III  hi      7  hi  Fc    RI          /lo  ) (  33  ). 
These cells develop exclusively into mast cells and basophils 
when cultured in a cocktail of cytokines that includes stem 
cell factor (SCF), IL-3, IL-5, IL-6, IL-7, IL-9, IL-11, GM-
CSF, erythropoietin (EPO), and thrombopoietin (TPO). 
In the present study, we used this system to examine the 
expression patterns of   FOG-1  ,   GATA-1  , and   GATA-2   
as primary cells commit to the mast cell/basophil lineage. 
As shown in   Fig. 1  , RT-PCR analysis reveals expression 
of   GATA-1  ,   GATA-2  , and   FOG-1   in hematopoietic stem 
cells, common myeloid progenitors, and megakaryocyte/JEM VOL. 205, March 17, 2008 
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GATA-2, we performed yolk sac colony assays from embryos 
containing knock-in mutations that disrupt the binding of 
FOG-1 to either GATA-1 (GATA-1  V205G  ) and/or GATA-2 
(GATA-2  V296G  ) (  9  ). As shown in   Fig. 2 A  , there is a slight 
expansion of mast cell colony numbers compared with the 
wild type in hemizygous GATA-1  V205G   males (    1.9-fold) 
and a moderate expansion in GATA-2  V296G/V296G   embryos 
(    6.2-fold), but a marked expansion in compound GATA-
1  V205G  , GATA-2  V296G/V296G   embryos (35-fold) to levels similar 
to those of FOG-1      /      embryos. These results indicate that 
direct binding of FOG-1 to GATA factors is required for its 
inhibitory activity on mast cell lineage commitment, and that 
GATA-1 and GATA-2 play overlapping roles. This   mirrors the 
overlapping FOG-dependent roles of GATA-1 and GATA-2 
in early megakaryocytic development (  9  ). 
  To test directly whether FOG-1 represses mast cell develop-
ment, we enforced   FOG-1   expression in prospectively isolated 
assays from FOG-1      /      mouse embryos. When yolk sac cells 
from embryonic day 9.5 FOG-1      /      embryos are grown un-
der conditions supporting multilineage growth (EPO, TPO, 
and SCF), there is a marked expansion of mast cell colonies 
(    47-fold) compared with the wild type (  Fig. 2 A  ).   Identifi  -
cation of the colonies was based on cell morphology and 
positive Toluidine blue staining (  Fig. 2 B  ). The absolute in-
crease in mast cell colony numbers (473   ±   69 per 10  5   cells 
plated) is signifi  cantly greater than the additive loss of mixed, 
erythroid, and megakaryocytic colonies (48   ±   9 per 10  5   cells 
plated), suggesting a true expansion of MCPs rather than a 
simple defaulting of multipotent progenitors to the mast cell 
lineage. These results imply that FOG-1 represses mast cell 
lineage commitment, possibly at the level of common my-
eloid progenitors or GMPs. 
  To determine whether this inhibition requires direct 
physical interaction between FOG-1 and GATA-1 and/or 
    Figure 1.         GATA-1 functions independent of FOG cofactors in mast cell development.   (A) Schematic diagram showing hierarchical relationships 
of the hematopoietic progenitor populations examined in B. (B) RT-PCR analysis of   GATA-1 ,   GATA-2  , and   FOG-1   expression in sorted progenitor cell 
populations, day 3 MCPs (d3 MCP), and peritoneal mast cells.   Fc  RI ,   MMCP-1  , and   MMCP-5   are included as mast cell  –  specifi  c marker genes.   HPRT  
serves as the housekeeping gene control. White lines indicate that intervening lanes have been spliced out. (C) RT-PCR analysis of   FOG-2   expression 
in BMMCs (from 6-wk-old cultures) or whole mouse heart tissue.   MMCP-2 ,   MMCP-4  , and   MC-CPA   are included as mast cell  –  specifi  c markers. 
(D) May-Grunwald-Giemsa stains and FACS analysis for Fc    RI and c-kit expression of YSMCs from wild-type, GATA-1       , or GATA-1  V205G(KI)   male 
embryos. Bars, 10    m.   614 FOG-1 IN MAST CELL DEVELOPMENT | Cantor et al.
cell growth conditions, and quantitated for mast cell growth 
by limiting dilution. An     2.5-fold greater number of GMPs 
was required to generate that same number of single cell mast 
cell clones from these transgenic mice compared with non-
transgenic littermates, suggesting a reduction in the number 
of MCPs in the transgenic mice (  Fig. 3 C  ). The somewhat 
modest eff  ect, relative to the in vitro studies, is likely caused 
by relatively weak expression of the transgene in the mast 
cell lineage. Nonetheless, our data collectively indicate that 
down-regulation of   FOG-1   expression is a prerequisite for 
mast cell development. 
  Reprogramming of primary mast cells into alternate 
lineages by ectopic expression of FOG-1 
  In the preceding experiments,   FOG-1   expression was en-
forced in early multipotent progenitor cells. We next exam-
ined the consequences of ectopic   FOG-1   expression in cells 
already committing to the mast cell lineage. In the fi  rst 
set of studies, we generated primary mast cells by culturing 
whole bone marrow in the presence of IL-3 and SCF for 
6 wk. FACS analysis of this starting cell population showed 
100% of the cells were c-kit  +  , Ter119        (erythroid marker), 
and 96% were Fc    RI  +   (not depicted). We then infected them 
with retroviruses packaged with the empty vector, FOG-1, 
or a missense FOG-1 mutant with impaired GATA factor 
binding (m1,5,6,9) (  40  ). We previously showed that the 
m1,5,6,9 FOG-1 protein is stable and properly targeted to 
the nucleus when expressed in a FOG-1  –  null hematopoietic 
GMPs using retroviruses and examined the ability of the cells 
to form mast cells in vitro in a limiting dilution assay (  Fig. 3  ).   
The retroviral vectors used coexpress enhanced GFP (eGFP) as 
a bicistronic mRNA, allowing for tracking of the transduced 
cells. As shown in   Fig. 3 A  , nearly all of the GFP  +   GMPs trans-
duced with the empty control vector and cultured for 3 wk in 
the presence of IL-3, IL-6, IL-9, and SCF express high levels of 
Fc    RI, contain granular cytoplasm, and lack expression of the 
granulocytic and monocyte/macrophage markers Gr-1 and 
CD11b. In contrast, GMPs transduced with   FOG-1    –  expressing 
retroviruses (GFP  +  ) are almost entirely Fc    RI       , lack signifi  cant 
granularity, and express CD11b and, to a lesser extent, Gr-1 
when cultured under identical conditions. 
  We also examined the eff  ect of enforced   FOG-1   expres-
sion on mast cell development in vivo. A transgene contain-
ing     7 kb of DNA sequence upstream of the fi  rst erythroid 
exon of   GATA-1   is suffi   cient to drive expression in erythroid 
and megakaryocytic cells and, albeit somewhat weakly, in 
mast cells and eosinophils (  36  –  38  ). Because no other well 
characterized mast cell  –  specifi  c transgenic promoters have 
been reported, we chose to use this     7-kb   GATA-1   up-
stream sequence to examine the consequences of enforced 
  FOG-1   expression on mast cell lineage commitment (  Fig. 3 B  ). 
We previously generated FOG-1 transgenic mice using this 
regulatory region and demonstrated that it rescues the hema-
topoietic defects of FOG-1      /      mice (  39  ). In this study, we 
examined the same transgenic line for mast cell production. 
GMPs were isolated from bone marrow, plated under mast 
    Figure 2.         Loss of FOG-1 results in an increased number of YSMC progenitors in vivo.   (A) Yolk sac cultures from WT, FOG-1     /   ,  GATA-1 V205G(KI)  
male, GATA-2  V296G/V296G(KI/KI)  , and compound GATA-1  KI ,  GATA-2 KI/KI   male embryonic day 9.5 embryos. Shown are numbers of mast cell, mixed (Mix), mega-
karyocytic (Meg), erythroid, and GM colonies per 10  5   cells plated and cultured in 2 IU/ml EPO, 5 ng/ml TPO, and rat 50 ng/ml SCF for 7 d. The number of 
animals analyzed for each is indicated above the graphs. Error bars represent the SEM. (B) Colony and cell morphology of mast cell colonies from GATA-1  KI , 
GATA-2  KI/KI   male embryos. (a) Brightfi  eld appearance of colony. Bar, 50     m. (b) May-Grunwald-Giemsa stain of cytospun cells. Bar, 10     m. (c) Toluidine 
blue stain of cytospun cells. Bar, 10    m.   JEM VOL. 205, March 17, 2008 
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cells appear hypogranular, with pale blue cytoplasm and large 
nuclei with an open chromatin pattern. Loss of granularity 
is evident by FACS analysis, which shows a marked reduction 
in cells with high side scattering compared with the control 
cells (after gating for viable cells). In addition,     25% of the via-
ble FOG-1  –  transduced cells lack surface expression of Fc    RI. 
  Remarkably, after culturing for an additional 5 d in the 
presence of EPO, TPO, IL-3, and SCF, cells resembling matur-
ing erythrocyte, megakaryocytic, and granulocytic cells became 
evident in the FOG-1  –  transduced sample (  Fig. 4 D  ). This was 
confi  rmed by staining with benzidine, which turns hemoglo-
binized cells a dark brown color, and for acetylcholinesterase, 
a marker of mouse megakaryocytes. Although the frequency 
of positive-staining cells was quite low (0.7   ±   0.4% benzidine 
positive and 0.5   ±   0.2% acetycholinesterase positive of 5,000 
cells examined each), no positive cells were observed in  >  5,000 
vector or m1,5,6,9-transduced cells examined. 
  One interpretation of these results is that ectopic FOG-1 
expression reprograms   “  committed  ”   MCPs into the erythroid, 
cell line (  10  ). All of the constructs coexpress eGFP as a bicis-
tronic mRNA. 2 d after retroviral infection, GFP  +   cells were 
sorted and incubated in the presence of IL-3, SCF, EPO, and 
TPO for various time points. Cells transduced with the empty 
vector or the non-GATA  –  binding FOG-1 mutant retained 
nearly 100% viability throughout the fi  rst 5 d of culture, as 
measured by vital dye exclusion (  Fig. 4 A  ).   In contrast, only 
    70% of the FOG-1  –  transduced cells   survived. Some of the 
cell death occurs via apoptosis, as   indicated by an increased 
number of Annexin V  +  /7-amino-actinomycin D        cells (  41  ) 
in the FOG-1 compared with the empty vector and m1,5,6,9 
FOG-1  –  transduced samples (7.1 vs. 1.8 vs. 2.1%, respectively) 
when examined 3 d after sorting (  Fig. 4 B  ). 
  By 6 d after FACS sorting, cells transduced with either the 
empty vector or the non-GATA  –  binding FOG-1 mutant show 
typical mast cell morphology by May-Grunwald-Giemsa stains. 
They are highly granular, as indicated by prominent side scatter 
on FACS analysis, and nearly all express Fc    RI on their cell 
surface (  Fig. 4 C  ). In contrast, many of the FOG-1  –  transduced 
    Figure 3.         Enforced expression of FOG-1 blocks mast cell development.   (A) FACS expression analysis for eGFP, Gr-1, CD11b, or Fc    RI in GMPs 
transduced with retroviruses expressing eGFP alone (vector) or FOG-1  –  IRES-GFP (FOG-1), and cultured at limiting dilution in the presence of SCF, IL-3, IL-6, 
and IL-9 for 3 wk. Percentages of total cells that fall within the boxed FACS gates are shown. May-Grunwald-Giemsa stains of the GFP  +   cells are shown 
on the right. Bars, 10     m. (B) Schematic representation of the transgene used to express FOG-1 in the mast cell lineage. Approximately 7 kb of DNA 5     to 
the fi  rst erythroid exon (1E) of   GATA-1   (noncoding) were used. Full-length FOG-1 cDNA was inserted into exon 2 of   GATA-1   upstream of the   GATA-1   start 
codon, followed by an SV40 polyA sequence (gray box). Exons are indicated by black boxes. (C) Limiting dilution analysis of bone marrow GMPs from FOG-1  –
  transgenic mice or wild-type littermates. The percentage of wells that failed to generate mast cells was scored, and the number of cells per well leading 
to a 37% detection failure rate was calculated.     616 FOG-1 IN MAST CELL DEVELOPMENT | Cantor et al.
expanded in IL-3 and SCF for an additional 4 wk. These cells 
were then infected with the empty vector or FOG-1  –  express-
ing retroviruses, sorted for GFP expression after 2 d, and cul-
tured in IL-3, SCF, EPO, and TPO for an additional 6 d. 
They were then analyzed by FACS analysis for surface ex-
pression of Fc    RI and Ter-119, an erythroid specifi  c marker. 
As shown in   Fig. 5 A  , essentially 100% of the vector-trans-
duced cells were Fc    RI  +   Ter-119       , which was consistent 
with the starting population being a clonal mast cell line.   In 
contrast, 22% of the FOG-1  –  transduced cells were Fc    RI       , 
12.6% were Ter-119  +  , and 2.5% were both Fc    RI        and 
Ter-119  +  . Interestingly, a continuum of Fc    RI  –  Ter-119  –
  coexpressing cells was observed, suggesting an overlapping 
transition from Fc    RI to Ter-119  –  expressing cells. 
  As a second approach, we prospectively isolated cell popu-
lations highly enriched in MCP cells (day 2 MCPs, which 
were GMPs cultured for 2 d in IL-3, SCF, and IL-6 and 
sorted for     7  hi  CD11b        expression) and repeated the FOG-1 
megakaryocytic, and granulocytic lineages. However, based 
on the results so far, we could not exclude the possibility that 
our cultures contain rare contaminating multilineage progeni-
tors, and that ectopic FOG-1 expression simply selects against 
cells committing to the mast cell lineage and for those com-
mitting to the erythroid, megakaryocytic, and granulocytic 
pathways. This seems unlikely because the starting cells were 
cultured for 6 wk in the presence of SCF and IL-3, conditions 
not expected to sustain multipotent progenitor cells. How-
ever, we took two approaches to address this possibility. First, 
we repeated the experiment using clonally derived primary 
mast cells. Because primary mast cells can be cultured for ex-
tended periods of time, it is possible to clone them at the single 
cell level. Whole bone marrow was cultured in the presence 
of IL-3 and SCF for 2 wk, and the cells were cloned by limit-
ing dilution. This was the latest time point possible to begin 
the cloning and still generate enough cells for retroviral infec-
tion and analysis before they senesced. A single cell clone was 
    Figure 4.         Ectopic expression of FOG-1 in BMMCs represses mast cell phenotype and produces alternate lineage cells.   (A) Percentage of viable 
GFP  +   primary BMMCs retrovirally transduced with eGFP alone (vector), FOG-1  –  IRES-eGFP (FOG-1), or m1,5,6,9 FOG-1  –  IRES-GFP (m1,5,6,9). Viability was 
determined by Trypan blue dye exclusion. Time refers to days after FACS sorting of eGFP  +   cells (2 d after retroviral infection). (B) FACS analysis for Annexin 
V (apoptosis marker) and 7-amino-actinomycin D (necrosis marker) expression of primary BMMCs transduced with each of the retroviral vectors de-
scribed in A and examined 3 d after FACS sorting of GFP  +   cells. Percentages of total cells that fall within the boxed FACS gates are shown. (C) May-Grun-
wald-Giemsa stains, FACS analysis showing side-scatter (SS) and forward scatter (FS), and Fc    RI expression of primary BMMCs transduced with each of 
the retroviral vectors shown in A, sorted for GFP after 2 d, and cultured for 6 d in 2 U/ml EPO, 5 ng/ml TPO, 10 ng/ml IL-3, and 50 ng/ml SCF. (bottom) The 
green lines represent negative control staining for Fc    RI (no IgE added; see Materials and methods). The purple histograms represent staining for Fc   RI 
(IgE added). The percentage in the middle panel represents the proportion of total stained cells present within the negative staining control peak area. Bar, 
10     m. (D) May-Grunwald-Giemsa, o-dianisidine (benzidine), and acetylcholinesterase (AChE) histochemical stains of the cultures in C incubated for an 
additional 5 d. Benzidine  +   cells stain black/brown; AChE  +   cells stain orange. The percentage of positive-staining cells is indicated (  ±  SEM;   n   = 2; 5,000 cells 
examined for all samples). Bar, 10    m.   JEM VOL. 205, March 17, 2008 
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cells maturing along the erythroid, megakaryocytic, and gran-
ulocytic lineages. RT-PCR analysis shows markedly dimin-
ished expression of   MMCP-2  ,   MMCP-4  , and   MC-CPA  , and 
activation of       -globin  ,   band 3  ,   EKLF  , and   GPIb      . Approx-
imately 4% of the cells were benzidine positive, and 5% ex-
pressed acetylcholinesterase based on histochemical staining (not 
depicted). These higher levels compared with those from 6-wk-
old primary BMMCs (  Fig. 4  ) are likely caused by an increased 
proportion of more immature MCPs, which may be more 
amenable to lineage reprogramming. Quantitative RT-PCR 
analysis of the retrovirally transduced MCPs shows   FOG-1   
transduction experiment (  Fig. 5 B  ). GFP  +   cells were sorted af-
ter 4 d, and the cells were cultured for an additional 5 d in 
the presence of SCF, IL-3, EPO, and TPO. As shown in   Fig. 5 
(C and D)  , cells transduced with the empty vector have a gran-
ular appearance, express the mast cell  –  specifi  c genes   MMCP-2  , 
  MMCP-4  , and   MC-CPA  , and lack expression of the ery-
throid- and megakaryocyte-specifi  c genes       -globin  ,   band 3  ,   
erythroid Kruppel-like factor   (  EKLF  ), and   glycoprotein Ib       (  GPIb      ) 
by RT-PCR analysis. Consistent with our earlier observation 
(  Fig. 4  ), most of the cells transduced with the FOG-1  –  expressing 
retroviruses lack typical mast cell morphology, and many resemble 
    Figure 5.         Ectopic expression of FOG-1 in MCPs blocks mast cell maturation and enables alternate lineage development.   (A) FACS analysis for 
TER119 and Fc    RI expression of clonal primary BMMCs retrovirally transduced with empty vector or FOG-1  –  IRES-eGFP  –  expressing retroviruses. GFP  +   cells 
were sorted 2 d after retroviral infection and cultured in EPO, TPO, IL-3, and SCF for 6 d. (B) Scheme for isolation and retroviral infection of day 2 MCPs. 
(C) May-Grunwald-Giemsa stains of day 2 MCPs transduced with empty vector, FOG-1, or the FOG-1 mutants m1,5,6,9,   	  N67, and   	  N67, mCTBP ex-
pressing retroviruses; cultured in mast cell media containing EPO, TPO, SCF, and IL-3 for 4 d; sorted for GFP expression (GFP  +   cells); and cultured for an 
additional of 5 d in mast cell media containing EPO, TPO, SCF, and IL-3. Boxes indicate cells seen in additional fi  elds. Bars, 10     m. (D) RT-PCR analysis for 
erythroid, megakaryocytic, and mast cell marker gene expression in the cells shown in C (harvested 5 d after sorting GFP  +   cells). (E) Quantitative RT-PCR 
analysis for   FOG-1   mRNA transcript levels in day 2 MCPs retrovirally transduced with the empty vector or FOG-1, sorted for GFP  +   expression after 4 d, 
and cultured for an additional 5 d in the presence of SCF, IL-3, EPO, and TPO. Levels are displayed relative to those determined in parallel from sorted 
mouse MEPs and normalized to   GAPDH   mRNA transcript levels. The relative signal from FOG-1     /     cells (reference   10  ) is shown as an indicator of experi-
mental background. All measurements were made in triplicate. The error bars represent the SEM.     618 FOG-1 IN MAST CELL DEVELOPMENT | Cantor et al.
NuRD and CtBP complexes, is required. We fi  rst examined 
a truncation FOG-1 mutant molecule (FOG-1   	  N67) that 
lacks the N-terminal 67 amino acids, a region that includes the 
entire NuRD interaction motif (  25  ). This molecule behaved 
similarly to the full-length protein when expressed in the day 
2 MCPs, although megakaryocytic development was not ob-
served, as expected (  Fig. 5 C  ) (  10  ). We then tested a double 
mutant that also substitutes the CtBP interaction motif PIDLS 
with the nonbinding sequence PIASS (  	  N67, mCTBP) (  24  ). 
This construct also blocks mast cell development and leads to 
activation of some erythroid-specifi  c genes (  Fig. 5, C and D  ). 
Although expression levels of these mutants were considerably 
higher than endogenous   FOG-1   levels in MEPs (    18-fold 
higher for   	  N67 and     150  –  fold higher for   	  N67, mCTBP 
as measured by quantitative RT-PCR analysis), these results 
suggest that mechanisms other than or overlapping with 
transcriptional corepression via the NuRD and CtBP com-
plexes are responsible for FOG-1  ’  s antagonistic role in mast 
cell development. 
expression levels close to those found physiologically in MEPs 
(  Fig. 5 E  ). As expected, only background levels of the FOG-1 
signal were detectable in the MCPs transduced with the empty 
vector based on comparison to FOG-1      /      cells. Collectively, 
these data strongly suggest that ectopic expression of FOG-1 
redirects committed MCP cells into alternate lineages. 
  Requirement for interaction with GATA factors but not 
CtBP and NuRD corepressor complexes 
  Next, we wanted to explore the mechanism of FOG-1  –  medi-
ated mast cell repression and lineage reprogramming. First, we 
tested whether this activity requires direct binding of FOG-1 
to GATA factors. As shown in   Fig. 5 C  , the non-GATA  –
  binding FOG-1 mutant m1,5,6,9 was inactive in day 2 MCP 
reprogramming, which was consistent with our earlier obser-
vations in YSMCs (  Fig. 2  ) and bulk BMMC cultures (  Fig. 4  ). 
Thus, direct binding to GATA factors appears necessary. 
We next tested whether interaction between FOG-1 and one 
or both of its known transcriptional corepressor partners, the 
    Figure 6.         FOG-1  –  mediated down-regulation of   GATA-2   expression correlates with GATA factor switching at the     2.8-kb   GATA-2   
enhancer element in mast cells.   (A) Quantitative RT-PCR analysis of   GATA-2   mRNA transcript levels in GFP  +   GMPs infected with retroviruses expressing 
either the empty vector (IRES-GFP) or FOG-1  –  IRES-GFP, sorted after 2 d, and analyzed immediately. Error bars represent SEM (  n   = 3). (B) ChIP assay exam-
ining occupancy of the   GATA-2      2.8-kb enhancer or the   Necdin   promoter by GATA-1, GATA-2, and/or FOG-1 in 4-wk-old BMMCs retrovirally transduced 
with either the empty vector (IRES-GFP) or FOG-1  –  IRES-GFP and sorted for GFP  +   cells after 2 d. A schematic drawing of the mouse   GATA-2   locus with the 
    2.8-kb enhancer element is indicated. 1S and 1G refer to different transcriptional start sites. Normal pooled rat IgG was used as the control for GATA-1 
ChIP, and FOG-1 preimmune rabbit serum served as the control for FOG-1 and GATA-2 ChIPs. The level of detected amplicon was normalized to a stan-
dard curve of input chromatin and is indicated as relative units. Error bars represent the SEM (  n   =  2).   JEM VOL. 205, March 17, 2008 
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acts cooperatively with GATA factors in erythroid and mega-
karyocytic diff  erentiation, it potently antagonizes GATA func-
tion in mast cell lineage commitment. This requires direct 
GATA factor binding and correlates with transcriptional 
down-regulation of   GATA-2   via a GATA factor switching 
mechanism. Moreover, we show that FOG-1, as a single fac-
tor, is capable of redirecting committed primary MCP cells 
into alternate lineage fates. This provides evidence for lineage 
plasticity during at least the early stages of hematopoietic lin-
eage commitment. 
  Down-regulation of FOG-1 in eosinophil development 
  Our results are strikingly similar to those reported by Querfurth 
et al. in their studies of eosinophil development (  45  ). Both 
eosinophils and mast cells require GATA-1 for complete matu-
ration (  46  ). Like mast cells,   FOG-1   expression is extinguished 
as eosinophils diff  erentiate from multipotent progenitor cells, 
and this is a prerequisite for their development. Moreover, ec-
topic expression of FOG-1 in an eosinophilic cell line changes 
it to a more primitive state. These fi  ndings highlight important 
parallels in the transcriptional control of eosinophil and mast 
cell development (  Fig. 7  ). 
  Combinatorial control of hematopoietic cell fate decisions 
by the   Drosophila   GATA factor   Serpent   (  Srp  ) and the FOG 
orthologue   U-shaped   (  Ush  ) 
  The combinatorial control of hematopoietic cell fate deter-
mination by GATA and FOG described in this paper is also 
reminiscent of that reported in studies of   Drosophila   hema-
topoiesis. The   Drosophila   hematopoietic system consists of 
multipotent hemocyte progenitor cells that give rise to one 
of three specialized cell types: plasmatocytes, crystal cells, 
and lamellocytes, all of which function in immune responses 
(for review see reference   47  ). Remarkably, most of the same 
  FOG-1  –  mediated down-regulation of GATA-2 in mast cells 
  High level   GATA-2   expression is required for mast cell devel-
opment (  28, 42  ). Grass et al. have studied the transcriptional 
regulation of   GATA-2   and identifi  ed a critical enhancer ele-
ment located     2.8 kb upstream of the 1S promoter that con-
tains phylogenetically conserved GATA consensus binding 
sequences (  43  ). Based on ChIP and transcriptional studies, they 
proposed a model in which GATA-2 occupies this site in early 
multipotent progenitor cells and autoactivates   GATA-2   gene 
transcription. As cells mature along the erythroid pathway and 
GATA-1 levels increase, occupancy of this enhancer element 
switches from GATA-2 to GATA-1, leading to repression of 
  GATA-2   transcription. In collaborative studies, we showed 
that this GATA factor switch depends on the presence of 
FOG-1 (  21  ). Moreover, FOG-1 rapidly and potently represses 
  GATA-2   expression in reconstituted FOG-1      /      cells, and 
the non-FOG  –  binding GATA-1 mutant GATA-1  V205G   fails to 
repress   GATA-2   transcription in reconstituted GATA-1  –  null 
erythroid cells (  8, 21  ). 
  Given GATA-2  ’  s essential role in mast cell development, 
we hypothesized that FOG-1  ’  s antagonist activity in mast cell 
development could be in part caused by GATA factor switch-
ing at the   GATA-2       2.8-kb enhancer and subsequent repres-
sion of  GATA-2   transcription ( 42, 44 ). To test this, we examined 
changes in   GATA-2   mRNA transcript levels at the earliest 
time point possible after FOG-1 retroviral overexpression in 
GMPs. As shown in   Fig. 6 A  , we observed a 2.7-fold reduc-
tion in   GATA-2   transcripts by quantitative RT-PCR in 
FOG-1  –   versus empty vector  –  transduced GMPs sorted 2 d 
after retroviral infection for GFP expression and analyzed 
immediately.   Because there are insuffi   cient numbers of cells 
to perform ChIP assays in GMPs, we expressed FOG-1 or the 
empty vector in BMMCs and examined occupancy of the 
    2.8-kb region immediately after sorting GFP  +   cells 2 d after 
infection. As shown in   Fig. 6 B  , control cells (empty vector) 
contain high levels of GATA-2, low levels of GATA-1, and 
no detectable FOG-1 (over background) at the     2.8-kb re-
gion, as expected. In contrast, signifi  cant levels of FOG-1 are 
detectable at the     2.8-kb site in the FOG-1  –  transduced cells, 
and there is a marked increase in GATA-1 and a decrease in 
GATA-2 occupancy compared with control cells. Only back-
ground levels of GATA-1, GATA-2, and FOG-1 were found 
at the control Necdin promoter, which does not contain GATA 
binding sites, in both vector- and FOG-1  –  transduced cells. 
Thus, FOG-1  –  mediated GATA factor switching at the     2.8-kb 
  GATA-2   enhancer occurs as an early event after ectopic 
expression in mast cells. Consequential down-regulation of 
  GATA-2   expression may therefore explain, at least in part, 
the mechanism of FOG-1  ’  s antagonistic activity in mast cell 
lineage commitment. 
    DISCUSSION   
  In this study, we use both loss- and gain-of-function ap-
proaches to demonstrate that FOG-1 acts in a combinatorial 
manner with GATA factors to specify the cell fate of multipo-
tent hematopoietic progenitor cells (  Fig. 7  ).   Although FOG-1 
    Figure 7.         Model of combinatorial control of erythrocyte/
megakaryocyte versus mast cell/eosinophil lineage commitment by 
GATA-1 and GATA-2 depending on the presence of FOG-1.   +  and 
     refer to the presence or absence, respectively, of expression of each 
gene. The arrows represent the favored differentiation pathway, and the 
gray   “  T  ”   bars represent the blocked differentiation pathway.     620 FOG-1 IN MAST CELL DEVELOPMENT | Cantor et al.
developing mast cells would preclude such a locus reconfi  gu-
ration and prevent effi   cient       -globin   gene expression. 
  FOG proteins interact with at least two transcriptional core-
pressor complexes, NuRD and CtBP. Rodriguez et al. demon-
strated promoter cooccupancy of the eosinophilic-specifi  c gene 
  MBP   by GATA-1, FOG-1, and the NuRD component MBD3 
in induced mouse erythroleukemia (MEL) cells, which was con-
sistent with FOG-1  –  mediated repression of eosinophil-specifi  c 
genes in erythroid cells via NuRD (  26  ). We hypothesized that 
FOG-1  ’  s repressive activity in mast cell development involves its 
recruitment of one or both of these complexes. However, a 
double mutant molecule incapable of binding either the NuRD 
or CtBP complexes was as potent as the wild-type molecule in 
repressing mast cell development from MCPs (  Fig. 5  ). Our re-
sults are consistent with a recent report showing that a double 
  	  N,   	  CtBP FOG-1 mutant represses GATA-1  –  dependent ac-
tivation of the   Fc    RI-       promoter as well as wild-type FOG-1 in 
transient transfection reporter assays in the PT18 mast cell line 
(  52  ). These results suggest that mechanisms other than recruit-
ment of the NuRD and/or CtBP complexes are responsible 
for FOG-1  ’  s inhibitory activity on mast cell development. 
  Regulation of FOG-1 expression 
  Regardless of the mechanism, our data, in combination with 
that of Querfurth et al., indicate that repression of   FOG-1   ex-
pression is critical for mast cell and eosinophil diff  erentiation 
from multipotent progenitors (  45  ). This begs a question: what 
turns off   FOG-1 during the development of these lineages? The 
transcriptional regulation of   FOG-1   is just beginning to be 
explored. Welch et al. used bioinformatics to predict critical 
cis-regulatory elements controlling   FOG-1   expression (  53  ). 
They showed that one such region, predicted cis-regulatory 
module 1, is occupied by GATA-1 in erythroid cells, which is 
consistent with their data indicating transcriptional up-regula-
tion of   FOG-1   by GATA-1. We examined this same region in 
primary mast cells and instead found relatively low GATA-1 
but high GATA-2 occupancy compared with induced MEL 
cells (unpublished data). In addition, histone 3 is markedly hypo-
acetylated in this region, compared with induced MEL cells, 
consistent with epigenetic silencing of FOG-1 in mast cells. 
Whether high level GATA-2 occupancy at predicted cis-regu-
latory module 1 is responsible for   FOG-1   down-regulation will 
require further studies. However, given our fi  ndings that 
FOG-1 represses   GATA-2   expression (  Fig. 6  ) (  8, 21  ), it is pos-
sible that cross-antagonistic regulatory loops exist between 
GATA-2 and FOG-1. In this model, high GATA-2 levels si-
lence   FOG-1   expression in maturing mast cells, leading to en-
hanced   GATA-2   expression and further   FOG-1   repression. 
Conversely, high FOG-1 levels in maturing erythroid/mega-
karyocytic cells inhibit   GATA-2   expression, leading to fur-
ther elevation of FOG-1 and reduced   GATA-2   expression. 
  Mast cells in human disease 
  Mast cells play important roles in human disease, including 
asthma and type I hypersensitivity reactions. They have also 
recently been implicated as key intermediaries of regulatory 
transcription factors required for mammalian hematopoiesis 
also play essential roles in   Drosophila   blood development (  48  ). 
The GATA orthologue   Srp   is required for hemocyte pre-
cursor, crystal cell, and plasmatocyte development. The FOG 
orthologue   Ush   is required for hemocyte precursor formation 
and plasmatocyte diff  erentiation. However, it is selectively 
down-regulated during crystal cell diff  erentiation (  49  ). This is 
essential for crystal cell formation, because enforced   Ush   ex-
pression ablates crystal cell development, paralleling our fi  nd-
ings of blocked mast cell development by enforced   FOG-1   
expression (  Fig. 3  ). Conversely, loss-of-function   Ush   mutants 
contain marked expansion of crystal cells and a reduced num-
ber of plasmatocytes, similar to the enhanced mast cell and im-
paired erythroid/megakaryocyte production we observe in 
FOG-1      /      yolk sac cultures (  Fig. 2  ). As in our fi  ndings, the 
eff  ects in   Drosophila   require direct binding of Ush to Srp, be-
cause an isoform of Srp that lacks the equivalent N-terminal 
zinc fi  nger of vertebrate GATA factors is immune to the in-
hibitory eff  ects of Ush (  50  ). 
  Collectively, these studies underscore how combinations 
of GATA and FOG family members control hematopoietic 
cell fate decisions. Given the broad developmental require-
ment for interaction between GATA and FOG family mem-
bers, such as GATA-4 and FOG-2 in cardiac and gonadal 
development, it is tempting to speculate that combinatorial 
GATA  –  FOG control mechanisms are involved in nonhema-
topoietic cell fate decisions as well. 
  Combinatorial control of cell fate decisions by transcription 
factors and cofactors 
  Transcription factor combinatorial control mechanisms of cell 
fate decisions have been appreciated for some time. How-
ever, few examples exist involving a transcription factor and 
a cofactor (i.e., transcription factor protein  –  protein inter-
actions). One could imagine several possible mechanisms by 
which such interactions could aff  ect gene programs in a lin-
eage-specifi  c manner: (a) the cofactor could alter the DNA 
affi   nity and/or sequence specifi  city of the transcription fac-
tor; (b) the cofactor could enzymatically alter the local chro-
matin structure, aff  ecting the accessibility of other transcription 
factors; (c) the cofactor could alter the locus conformation by 
bridging the transcription factor to another sequence-specifi  c 
DNA binding protein; and (d) the cofactor could sequester 
the transcription factor. 
  Our data are consistent with a novel mechanism in which 
FOG-1 mediates the switching of two transcription factor 
family members at specifi  c loci to yield distinct transcriptional 
outcomes. The molecular details of this switching event re-
main to be determined. Our data do not exclude the possibil-
ity of additional mechanisms operating. Vakoc et al. recently 
used chromosome conformation capture to show that inter-
action between GATA-1 and FOG-1 is required for spatial 
proximity of the distant upstream       -globin   locus control re-
gion to the       -globin   gene proximal promoter during erythroid 
development (  51  ). This DNA looping event correlates with 
the onset of       -globin   transcription. The absence of FOG-1 in JEM VOL. 205, March 17, 2008 
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haps be considered more relative, rather than absolute, refl  ecting 
what the cell would do if left unperturbed. As the cell matures, 
lineage choices may become increasingly stabilized by tran-
scriptional networks involving positive autoregulation and 
cross-antagonism of alternate lineage transcription factors and 
cofactors. Is there a point of no return? That is, is there a point 
in diff  erentiation when reprogramming is not possible? When 
we attempted to reprogram more mature BMMCs (sorted for 
Fc    RI surface expression), as opposed to MCPs, we observed 
mostly cell death (unpublished data). Further understanding 
the mechanisms that mediate the transition from   “  reversible  ”   
to   “  irreversible  ”   lineage commitment will be of interest and, 
possibly, clinical utility in the future. 
  MATERIALS AND METHODS 
  Materials and constructs.     All cytokines were recombinant preparations 
purchased from R  &  D Systems unless otherwise stated. Antibodies for FACS 
staining were obtained from BD Biosciences unless otherwise stated. The 
mutant FOG-1 constructs have been previously described (  10  ). The   	  N67, 
mCTBP FOG-1 double mutant was constructed by recombining the   	  N67 
and mCtBP FOG-1 mutants. 
  Mouse strains.     Previous papers have described the generation of the 
GATA-1        (  3  ), FOG-1      /      (  7  ), GATA-1  V205G   (  9  ), GATA-2  V296G/V296G   (  9  ), 
and FOG-1 transgenic mice (  39  ) used in this study. All experiments involv-
ing mice were approved by the Children  ’  s Hospital Boston Animal Care 
and Use Committee and conform to institutional regulatory standards. 
  YSMCs.     Collagenase-released yolk sac cells were cultured in methylcellu-
lose (StemCell Technologies Inc.) in the presence of 5 ng/ml mTpo, 2 IU/ml 
hEpo, and 50 ng/ml of rat SCF (Amgen), as previously described (  9  ). Colonies 
were scored after 7 d of culture. Cytospins of colonies were performed and 
analyzed by May-Grunwald-Giemsa and Toluidine blue staining to confi  rm 
colony type. 
  Generation of YSMCs and BMMCs.     For YSMCs, pregnant females 
were killed at 9.5 d after coitus. Yolk sacs were dissected away from the em-
bryos, digested with 0.1% (wt/vol) collagenase (Worthington Biochemical 
Corp.) in 20% FCS/calcium and magnesium-free 1  ×   PBS for 90 min at 
37  °  C with agitation, passaged 8  ×   through an 18-gauge needle, and placed in 
IMDM (Invitrogen) containing 15% FCS. The suspension was centrifuged, 
and the cell pellets were cultured in IMDM containing 15% FCS, penicillin/
streptomycin, gentamicin, 10 ng/ml of mouse IL-3, and 50 ng/ml of mouse 
SCF (mast cell growth media) for 6 wk (unless stated otherwise in the fi  gure 
legends), splitting the cell cultures as needed. 
  For BMMCs, adult male C57/BL6 mice were killed and both femurs 
were removed. The marrow cavity was fl  ushed with IMDM containing 15% 
FCS. The samples were vortexed and allowed to sit at room temperature for 
5 min to allow large debris to settle. The supernatant was centrifuged, and 
the cell pellet was resuspended in mast cell growth media. Cells were cul-
tured in mast cell growth media for 6 wk (unless stated otherwise in the 
text), splitting the cell cultures as needed. 
  Limiting dilution analysis of MCPs from transgenic mice.     GMPs 
were purifi  ed from wild-type or FOG-1  –  transgenic mice, as previously de-
scribed (  70  ), and plated on 96-well culture plates containing mast cell growth 
media at graded cell numbers using an automatic cell deposition unit system. 
Cells were cultured for 4 wk and examined in cytospin preparations. Wells 
positive for mast cell growth were determined morphologically by May-
Grunwald-Giemsa and Toluidine blue staining. 
  Isolation of MCP cells.     For day 2 MCP sorting, purifi  ed GMPs were cul-
tured for 48 h in IMDM containing 20% FBS in the presence of 50 ng/ml 
T cell  –  mediated immune tolerance (  54  ). Our data provide 
new insights into the molecular control of mast cell develop-
ment and suggest possible novel approaches to manipulating 
mast cell  –  related processes. In theory, derepression of   FOG-1   
in maturing MCPs should inhibit their production and, pos-
sibly, alleviate the secondary eff  ects of mast cell release. 
  Mastocytosis refers to a heterogeneous group of disorders 
associated with inappropriate or nonatopic expansion of mast 
cells. It ranges in clinical severity from localized cutaneous 
mastocytosis to aggressive systemic mastocytosis. Activating 
mutations in c-kit or interstitial chromosome 4 deletions that 
generate a constitutively active FIP1LI  –  PDGFA fusion re-
ceptor tyrosine kinase have been identifi  ed in many, but not 
all, cases of systemic mastocytosis (  55  –  57  ). Based on our data, 
it is intriguing to speculate that acquired FOG-1 loss-of-function 
mutations in early multipotent progenitor or stem cells might 
also cause or contribute to clonal mast cell expansion in some 
cases, particularly those with associated eosinophilia and/or my-
elodysplasia. Examination of such a possibility seems warranted. 
  Lineage plasticity during the early stages of hematopoietic 
differentiation 
  The classical view of hematopoietic development is one in 
which multipotent progenitor cells irreversibly commit to dis-
tinct lineage types during diff  erentiation. However, beginning 
with the work of Boyd and Schrader (  58  ), the irreversibility of 
these decisions has been questioned (  59  –  63  ). Although most of 
the early studies used transformed cell lines, more recent work 
using primary cell and in vivo systems support the initial fi  nding 
(  64  –  69  ). Our results provide further evidence for lineage plastic-
ity during at least the early stages of hematopoietic cell fate com-
mitment. Although we cannot completely exclude the possibility 
of selection of rare contaminating multipotent progenitors cells 
in our system, several aspects of our fi  ndings suggest that the 
FOG-1  –  mediated block in mast cell development and the ap-
pearance of alternate lineage cells represents true   “  reprogram-
ming.  ”   First, MCPs were prospectively isolated in two rounds 
of immunophenotypic cell sorting before FOG-1 transduction. 
Second, FOG-1 reprogramming activity was observed in clonal 
primary mast cells (and the parent clone was 100% Fc    RI posi-
tive and Ter119 negative after culture in multilineage-supporting 
cytokine cocktails). Third, the block in mast cell development 
and the appearance of abundant alternate lineage cells appears 
rapidly (over 6  –  11 d), which seems unlikely if it represents the 
selection of a very rare contaminating multipotent progenitor 
cell in the original retrovirally infected cell population. 
  Although it seems unlikely that FOG-1  –  induced lineage 
switching of MCPs occurs physiologically, the fi  ndings demon-
strate the potential for such plasticity. Whether this occurs via 
direct transdiff  erentiation of MCPs to erythroid/megakaryocytic 
cells or via dediff  erentiation followed by rediff  erentiation along 
erythroid/megakaryocytic pathways remains to be determined. 
  Our results, collectively with those of others described in 
this section, support a model of   “  lineage instability  ”   during 
the early stages hematopoietic cell fate determination. In this 
developmental window, the term   “  commitment  ”   should per-622 FOG-1 IN MAST CELL DEVELOPMENT | Cantor et al.
with 1% formaldehyde (fi  nal concentration) for 10 min at room temperature, 
and the reaction was stopped by adding excess glycine. Nuclei were lysed and 
the chromatin was sonicated to generate    500  –  1,000-bp fragments. Immuno-
precipitation was performed using anti-GATA-1 (N6; Santa Cruz Bio  -
te  chnologies), followed by rabbit anti  –  rat IgG (Jackson ImmunoResearch 
Laboratories), anti-GATA-2 (H-116; Santa Cruz Biotechnologies), or anti  –
  FOG-1 polyclonal antisera (  6  ), or the equivalent protein amount of pooled 
normal rat IgG (Sigma-Aldrich) or FOG-1 preimmune sera. After washing, 
the cross-links were reversed and the released DNA fragments were purifi  ed 
by phenol-chloroform extraction and ethanol precipitation. Recovery of 
specifi  c DNA fragments was assessed by real-time PCR (My-Cycler or iCy-
cler; Bio-Rad Laboratories) and normalized to a serial dilution standard curve 
of input chromatin for each reaction. PCR primer sets are as follows:   Necdin   
promoter, 5    -GGTCCTGCTCTGATCCGAAG-3     and 5    -GGGTCGCT-
CAGGTCCTTACTT-3    ; and   GATA-2       2.8 kb, 5    -GCATGGCCCTG-
GTAATAGCA-3     and 5    -CAGCCGCACCTTCCCTAA-3    . 
  Online supplemental material.     Fig. S1 examines the morphology and 
marker gene expression of YSMCs and BMMCs. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20070544/DC1. 
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